Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
33.5M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
16.9M
-
Shares change
-
+16.9M
-
Total reported value, excl. options
-
$170M
-
Value change
-
+$170M
-
Number of buys
-
23
-
Price
-
$10.02
Significant Holders of Drugs Made In America Acquisition Corp. - Common (DMAA) as of Q1 2025
23 filings reported holding DMAA - Drugs Made In America Acquisition Corp. - Common as of Q1 2025.
Drugs Made In America Acquisition Corp. - Common (DMAA) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.9M shares
of 33.5M outstanding shares and own 50.59% of the company stock.
Largest 10 shareholders include Karpus Management, Inc. (2.32M shares), First Trust Capital Management L.P. (2.07M shares), Polar Asset Management Partners Inc. (1.9M shares), GLAZER CAPITAL, LLC (1.82M shares), Hudson Bay Capital Management LP (1.8M shares), Westchester Capital Management, LLC (979K shares), ARISTEIA CAPITAL, L.L.C. (900K shares), Quarry LP (650K shares), WOLVERINE ASSET MANAGEMENT LLC (603K shares), and ATW SPAC MANAGEMENT LLC (570K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.